Parkinson’s motor symptoms linked to overactive bladder
Japanese research shows that men with Parkinson’s disease are significantly more likely to experience symptoms of overactive bladder if they have finger taps or constipation.
Conclusion: PFD is common in CC patients after treatment. LRH seems to increase the postoperative distress, including LUTS and defecation symptoms. Postoperative urinary incontinence and OAB are more bothersome for patients undergoing chemotherapy and radiotherapy. We recommend evaluating pelvic floor function as a standard assessment during follow-up.Gynecol Obstet Invest
Prog Urol. 2021 Jul 23:S1166-7087(21)00165-2. doi: 10.1016/j.purol.2021.05.005. Online ahead of print.ABSTRACTPURPOSE: The safety of mirabegron 50mg monotherapy was comprehensively assessed versus placebo for overactive bladder.METHODS: A systematic literature search was conducted up to June, 2020 using PUBMED, EMBASE and Cochrane Library. Randomized controlled trials evaluating safety of mirabegron in overactive bladder were collected, and safety was assessed according to 15 adverse events. Adverse events were widely selected to be assessed if they could be calculated. Heterogeneity among studies was assessed by using the...
Nowadays there is still no ideal treatment for paediatric overactive bladder. Initial management measures (urotherapy and constipation control), resolve 40% of cases. The second line of treatment in overactive bladder is anticholinergic drugs, above all oxybutynin. Although most patients improve with these therapies, the complete resolution rate is around 30-40%. Sacral transcutaneous electrical nerve stimulation has recently emerged as a new alternative in the management of patients with refractory paediatric overactive bladder.
Conclusion: Both mirabegron and solifenacin have comparable efficacy regarding the control of OAB symptoms in the newly diagnosed children, but mirabegrone seems to have less side effects.Urol Int
A new drug combination appears to significantly reduce symptoms of schizophrenia compared with placebo, according to theresults of a phase 2 trial published this week in theNew England Journal of Medicine.The drugs are xanomeline, which has shown promise for Alzheimer ’s disease, and trospium chloride, which is approved for overactive bladder and has been shown to reduce some of the gastrointestinal side effects of xanomeline.Steven K. Brennan, M.D., chief medical officer of Karuna Pharmaceuticals, and colleagues randomly assigned 90 adults aged 18 to 60 with schizophrenia to receive twice-daily xanomeline-trospium a...
Conclusions Vibegron was effective and well tolerated in the treatment of a pediatric patient with NDO. Vibegron improved the urodynamic parameters for anticholinergic-resistant neurogenic bladder. This agent can be a beneficial and preferable alternative therapeutic agent to anticholinergics in patients with anticholinergic-resistant NDO.
Anticholinergic drugs used to treat overactive bladder (OAB), have common side effects, including constipation, dry eyes and dry mouth. They can also cause central nervous system effects such as confusion and reduction in cognitive function . Polypharmacy and an increase in blood brain barrier permeability increase these effects  which, are more likely in the elderly  as aging, as well as trauma, multiple sclerosis, hypertension, stroke and diabetes , leads to increased blood brain barrier permeability.
ConclusionImidafenacin demonstrated efficacy and safety in the treatment of OAB in Taiwanese patients.
This study was performed to investigate the relationship between each LUTD and its associated symptoms, using uroflowmetry/electromyography (UF/EMG) as a diagnostic tool.MethodsEach patient was categorized into one of four LUT conditions which were overactive bladder (OAB), dysfunctional voiding (DV), underactive bladder and primary bladder neck dysfunction (PBND), according to UF/EMG results. Patients' complaints and findings were documented by using voiding dysfunction symptom score, bladder diary, urine analysis and ultrasonography. In addition, a detailed history of bowel habits (including use of Rome III criteria) was...
ConclusionsThis study indicates that the safety and efficacy profile of mirabegron remains favorable compared with antimuscarinics among older adults. This includes safety outcomes typically associated with anticholinergic burden, which were less frequently observed in patients treated with mirabegron.